Latest news with #KRAS-driven
American Military News
11 hours ago
- Health
- American Military News
Experimental vaccine may prevent recurrence of cancer
Researchers recently discovered that an experimental cancer vaccine offers 'a promising approach' to preventing pancreatic and colorectal cancers from coming back after treatment. In a recent press release, UCLA Health announced that in a phase 1 clinical trial, which was backed by the UCLA Health Jonsson Comprehensive Cancer Center, researchers tested a cancer vaccine that can 'trigger powerful and lasting immune responses and may help prevent or delay cancer recurrence in high-risk patients whose tumors are driven by KRAS mutations.' The vaccine was tested on 25 patients who had received treatment for colorectal cancer and pancreatic cancer. According to the UCLA Health press release, the patients who participated in the study completed surgery to have their tumors removed and showed 'signs of minimal residual disease,' which indicated that they had a high risk of cancer recurrence. The UCLA Health press release noted that 21 of the 25 patients generated 'KRAS-specific T cells,' which suggests a stronger immune response than typical cancer patients. Cancer patients with higher T-cell responses exhibited 'longer relapse-free survival' compared to patients with lower T-cell responses. Additionally, the biomarkers for the cancer of three pancreatic cancer and three colorectal patients who received the vaccine appeared to be completely removed, according to UCLA Health. READ MORE: Pics: Child cancer survivor DJ Daniel diagnosed with 3 new tumors, White House says Researchers explained that a majority of the patients who displayed the strongest immune response remained free of cancer almost 20 months after receiving the cancer vaccine. 'This is an exciting advance for patients with KRAS-driven cancers, particularly pancreatic cancer, where recurrence after standard treatment is almost a given and effective therapies are limited,' Zez Wainberg, M.D., a professor of medicine at the David Geffen School of Medicine at UCLA and the author of the recent study, said. 'We observed that patients who developed strong immune responses to the vaccine remained disease-free and survived for much longer than expected.' The recent UCLA Health press release noted that 67% of the patients tested for the cancer vaccine developed 'immune responses to additional tumor-associated mutations.' Researchers suggested that the development of the immune responses indicated the potential for 'broader anti-tumor activity.' 'Targeting KRAS has long been considered one of the difficult challenges in cancer therapy,' Wainberg stated. 'This study shows that the ELI-002 2P vaccine can safely and effectively train the immune system to recognize and fight cancer-driving mutations. It offers a promising approach to generating precise and durable immune responses without the complexity or cost of fully personalized vaccines.'
New York Post
2 days ago
- Health
- New York Post
Promising cancer vaccine could prevent recurrence of pancreatic, colorectal tumors
An experimental cancer vaccine has shown promise in keeping certain cancers from coming back. In a phase 1 clinical trial led in part by the UCLA Health Jonsson Comprehensive Cancer Center, researchers tested the vaccine (ELI-002 2P) with 25 patients who had been treated for pancreatic and colorectal cancer. Advertisement The patients had all undergone surgery to remove tumors and showed 'signs of minimal residual disease' or traces of DNA, putting them at a high risk of recurrence, according to a UCLA press release. More than 80% of pancreatic cancer patients experience recurrence of the disease after surgery, research shows — and for 40% to 50%, this happens within the first year. For colorectal cancer, the recurrence rate is between 30% and 50% and is most likely to occur within the first two years after surgery. Mutations in the KRAS gene are responsible for half of colorectal cancers and more than 90% of pancreatic cancers. The vaccine, which targets those mutations, was given via a series of injections to activate an immune response in the lymph nodes. Advertisement 4 A phase 1 clinical trial indicates that a vaccine may prevent pancreatic and colorectal cancer from coming back. InsideCreativeHouse – A majority (21 out of 25) of the patients generated 'KRAS-specific T cells,' which indicates a stronger immune response. The ones with higher T-cell responses showed a longer relapse-free survival compared to those with lower responses, the researchers found. For three colorectal cancer patients and three pancreatic cancer patients, the vaccine appeared to remove all disease biomarkers. Among the patients who showed the strongest immune response, a majority were still cancer-free nearly 20 months after receiving the vaccine. Advertisement 4 The vaccine appeared to remove all disease biomarkers for three colorectal cancer patients out of the 25 pancreatic and colorectal cancer patients that were part of the trial. Jo Panuwat D – The findings were published in Nature Medicine. 'This is an exciting advance for patients with KRAS-driven cancers, particularly pancreatic cancer, where recurrence after standard treatment is almost a given and effective therapies are limited,' said first author of the study, Zev Wainberg, M.D., professor of medicine at the David Geffen School of Medicine at UCLA and researcher in the UCLA Health Jonsson Comprehensive Cancer Center, in the release. 'We observed that patients who developed strong immune responses to the vaccine remained disease-free and survived for much longer than expected.' Advertisement 4 'We observed that patients who developed strong immune responses to the vaccine remained disease-free and survived for much longer than expected,' Zev Wainberg, M.D., the first author of the study, said. manassanant – 'The new cancer vaccine from UCLA is very promising as a major tool against these cancers.' In another finding, 67% of the patients in the trial showed immune responses to 'additional tumor-associated mutations,' indicating that the vaccine could be used to suppress 'broader anti-tumor activity.' One of the benefits of ELI-002 2P, according to the researchers, is that it's considered 'off-the-shelf,' which means it's a mass-produced, standardized vaccine that doesn't have to be personalized for each individual patient. 'This study shows that the ELI-002 2P vaccine can safely and effectively train the immune system to recognize and fight cancer-driving mutations,' Wainberg said. 4 67% of the patients in the trial showed immune responses to 'additional tumor-associated mutations,' indicating that the vaccine could be used to suppress 'broader anti-tumor activity.' – 'It offers a promising approach to generating precise and durable immune responses without the complexity or cost of fully personalized vaccines.' The team has already finished enrolling participants for a phase 2 study that will test ELI-002 7P, the next iteration of the vaccine that will target a 'broader set' of KRAS mutations, the release stated. Advertisement The study was sponsored and funded by Elicio Therapeutics, the Massachusetts company that developed the vaccine. It was conducted in conjunction with the MD Anderson Cancer Center and the Memorial Sloan Kettering Cancer Center. Dr. Marc Siegel, Fox News senior medical analyst, was not involved in the study but commented that targeted therapies are becoming increasingly important tools in the fight against cancer. Advertisement 'Solid tumors, especially pancreatic, can be difficult to treat because they are not as mutagenic (capable of inducing or causing mutations) as hematological malignancies (blood cancers) or melanoma, for example, so they don't have as many ready targets for immunotherapy,' he told Fox News Digital. 'The new cancer vaccine from UCLA is very promising as a major tool against these cancers, as it 'programs' the immune system to target these mutations and has been shown in the NATURE study to elicit a strong clinical response.'
Business Upturn
01-08-2025
- Business
- Business Upturn
Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds
Cayman Islands, July 31, 2025 (GLOBE NEWSWIRE) — Silexion Therapeutics Corp. (NASDAQ: SLXN) ('Silexion Therapeutics' or the 'Company'), a clinical-stage biotech company developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 152,106 of the Company's ordinary shares originally issued in January 2025 at a reduced exercise price of $11.57 per share. The ordinary shares issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (File No. 333-282932) and an effective resale registration statement on Form S-1 (No. 333-284873). The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $1.8 million, prior to deducting placement agent fees and estimated offering expenses. The offering is expected to close on or about August 1, 2025, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering as working capital for general corporate purposes. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. In consideration for the immediate exercise of the warrants for cash, the Company will issue new unregistered warrants to purchase up to 304,212 of the Company's ordinary shares. The new warrants will have an exercise price of $11.32 per share, will be exercisable upon the effective date of the increase of the Company's authorized ordinary shares following shareholder approval and will have a term of twenty-four months from the effective date of the Resale Registration Statement (as defined below). The new warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended (the '1933 Act') and, along with the ordinary shares issuable upon their exercise, have not been registered under the 1933 Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission ('SEC') or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement with the SEC covering the resale of the ordinary shares issuable upon exercise of the new warrants (the 'Resale Registration Statement'). This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. About Silexion Therapeutics Silexion Therapeutics Corp is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations, the most common oncogenic driver in human cancers. The Company's first-generation product, LODER™, has shown promising results in a Phase 2 trial for non-resectable pancreatic cancer. Silexion is also advancing its next-generation siRNA candidate, SIL-204, designed to target a broader range of KRAS mutations and showing significant potential in preclinical studies. The company remains committed to pushing the boundaries of therapeutic innovation in oncology, with a focus on improving outcomes for patients with difficult-to-treat cancers. For more information please visit: Notice Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact contained in this communication, including statements regarding the completion of the offering, the satisfaction of customary closing conditions related to the offering and the intended use of net proceeds from the offering. These forward-looking statements are generally identified by terminology such as 'may', 'should', 'could', 'might', 'plan', 'possible', 'project', 'strive', 'budget', 'forecast', 'expect', 'intend', 'will', 'estimate', 'anticipate', 'believe', 'predict', 'potential' or 'continue', or the negatives of these terms or variations of them or similar terminology. For example, the Company is using forward-looking statements when it discusses the timing and completion of the offering, the satisfaction of customary closing conditions related to the offering and the intended use of proceeds therefrom. Forward-looking statements involve a number of risks, uncertainties, and assumptions, and actual results or events may differ materially from those projected or implied in those statements. Important factors that could cause such differences include, but are not limited to: (i) whether Silexion is able to successfully complete preclinical studies and initiate clinical trials; (ii) Silexion's strategy, future operations, financial position, projected costs, prospects, and plans; (iii) the impact of the regulatory environment and compliance complexities; (iv) expectations regarding future partnerships or other relationships with third parties; (v) Silexion's future capital requirements and sources and uses of cash, including its ability to obtain additional capital; and (vi) whether Silexion succeeds at maintaining the listing of its securities on the Nasdaq Capital Market. Silexion cautions you against placing undue reliance on forward-looking statements, which reflect current beliefs and are based on information currently available as of the date a forward-looking statement is made. Forward-looking statements set forth herein speak only as of the date they are made. Silexion undertakes no obligation to revise forward-looking statements to reflect future events, changes in circumstances, or changes in beliefs, except as otherwise required by law. Company Contact: Silexion Therapeutics CorpMs. Mirit Horenshtein Hadar, CFO [email protected]
Yahoo
30-05-2025
- Business
- Yahoo
Silexion Therapeutics announces preclinical results on SIL204
Silexion Therapeutics (SLXN) announced compelling preclinical data demonstrating the efficacy of its next-generation RNAi therapeutic candidate, SIL204, against human pancreatic, colorectal and lung, NSCLC, cancer cell lines. These results significantly expand SIL204's therapeutic potential beyond pancreatic cancer, allowing it to potentially address major KRAS-driven cancers with substantial unmet medical needs. Following the Company's recent announcement of completion of preclinical studies, a comprehensive analysis of the data has revealed that SIL204 effectively inhibited the proliferation and metabolic activity of human cancer cell lines harboring KRAS G12D mutations across multiple cancer types, resulting in the following obvervations: The data reveals SIL204 successfully inhibited the proliferation and metabolic activity of human cancer cell lines harboring a specific KRAS mutation: GP2D, A427 and Panc-1, in a statistically significant manner. The significant inhibition was observed in a dose-dependent manner down to nanomolar concentrations. As observed in the left hand graph below, a dose-dependent reduction in cell viability was noted in GP2D colorectal cancer cells, even in the absence of external additives, due to the lipid end of SIL204. Notably, as can be seen in the right hand graph below, the Company observed an inhibition rate of approximately 90% in the presence of SIL204 in GP2D colorectal cancer cells. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on SLXN: Disclaimer & DisclosureReport an Issue Silexion Therapeutics Receives Nasdaq Delisting Notice Silexion Completes Key Preclinical Studies for SIL204 Silexion Therapeutics completes preclinical studies on SIL204 Silexion Therapeutics' Promising Future: Buy Rating Backed by Expanding Market Potential and Strong Financial Position Silexion Therapeutics Partners with Catalent for SIL204 Development
Yahoo
30-05-2025
- Business
- Yahoo
Silexion Therapeutics Corp (SLXN)'s RNAi Therapy Blocks 90% of Colorectal Tumors
Silexion Therapeutics Corp (NASDAQ:SLXN) has announced breakthrough preclinical results for its next-generation RNA interference (RNAi) therapy, SIL204, showing potent anti-tumor effects across three major KRAS-driven cancers: pancreatic, colorectal, and lung (NSCLC). In laboratory studies, SIL204 achieved an impressive ~90% inhibition rate in GP2D human colorectal cancer cells, with significant, dose-dependent reductions also observed in pancreatic (Panc-1) and lung (A427) cancer cell lines harboring the KRAS G12D mutation. This marks a major advance, as KRAS mutations are among the most common and challenging targets in oncology, driving roughly 90% of pancreatic, 45% of colorectal, and 35% of non-squamous NSCLC cases. A hand holding cancer cells with a magnifying glass, highlighting the company's target of curing diseases. SIL204's innovative lipid-conjugated delivery system enhances cellular uptake, enabling high efficacy at nanomolar concentrations and potentially overcoming resistance that limits conventional therapies. The company plans further preclinical studies focusing on lung cancer cell lines to expand the evidence base. With a global market opportunity exceeding $30 billion for these cancer types, Silexion Therapeutics Corp (NASDAQ:SLXN)'s RNAi approach could reshape treatment options for patients with hard-to-treat, KRAS-driven tumors. While we acknowledge the potential of SLXN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SLXN and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None.
